Celladon Corporation to Present at Credit Suisse Healthcare

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Celladon Corporation to Present at Credit Suisse Healthcare Conference

SAN DIEGO, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq: CLDN ), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.

Details of the Presentation

Date:   November 12
Time:   11:30 a.m. Mountain Time
Presenter: Dr. Krisztina Zsebo, Chief Executive Officer
Location:   Arizona Biltmore Hotel, Scottsdale, Arizona
Webcast:   http://cc.talkpoint.com/cred001/111114a_jw/?e...81_401CO42

The live webcast and an archived presentation following the event will be available on the Investor Relations section of Celladon's corporate website at www.celladon.com .

About Celladon

Celladon is a clinical-stage biotechnology company applying its leadership position in the field of cardiovascular gene therapy to develop novel therapies for diseases with tremendous unmet medical needs. Our lead programs target SERCA enzymes which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, vascular disease, diabetes and neurodegenerative diseases. MYDICAR, the Company's most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with advanced heart failure. Celladon has completed enrollment of a 250 patient Phase 2b clinical trial evaluating the efficacy of MYDICAR in reducing the frequency of, or delaying heart failure-related hospitalizations. This randomized, double-blind, placebo-controlled, multinational trial is evaluating a single intracoronary infusion of MYDICAR versus placebo added to a maximal, optimized heart failure regimen in patients with New York Heart Association class III or IV symptoms of chronic heart failure due to systolic dysfunction. The Company has received Breakthrough Therapy designation from the FDA for this MYDICAR program and expects to report results from the Phase 2b clinical trial in April 2015. In addition, the Company conducts research and development on its mSCF gene therapy program for cardiac diseases. Celladon has also identified a number of potential first-in-class compounds addressing novel targets in diabetes and neurodegenerative diseases with its small molecule platform of SERCA2b modulators. For more information, please visit www.celladon.com .

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding its research and development programs and the expected timing for reporting data from the Phase 2b clinical trial of MYDICAR in patients with systolic heart failure. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Celladon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the process of conducting product development activities and clinical trials and obtaining regulatory approval to commercialize product candidates, our reliance on third parties, the need to raise additional funding when needed in order to conduct our business, and the degree of market acceptance of MYDICAR by physicians, patients, third-party payors and others in the medical community. These and other risks and uncertainties are described more fully in Celladon's filings with the Securities and Exchange Commission, including without limitation its Form 10-Q for the quarter ended June 30, 2014. All forward-looking statements contained in this press release speak only as of the date on which they were made. Celladon undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Fredrik Wiklund Vice President, Corporate Development and Investor Relations +1- 858-432-7215

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 30

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 144

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 33

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 67

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 232

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 50

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 65

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 124

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 9

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading

Top 5 Most Recently Viewed Articles

San Jose Workers Ready to Strike Amid Contract Woes

Updated Category News Views 87

Strike Looms Over San Jose City Workers Can't say I blame these San Jose city workers. They're at their wits' end, caught in what's feeling like an endless round of negotiations that just aren't getting anywhere. July 29 saw hundreds of city employees packed into Strike School sessions, seriously gearing up for what's looking like a showdown with city officials. Ain't a...

Continue Reading
Foot Health Revolution: Custom Orthotic Insoles Lead Market Surge

Updated Category News Views 70

Understanding the Custom Foot Orthotic Insoles Market Growth The Custom Foot Orthotic Insoles Market is experiencing remarkable growth driven by a series of key factors. The increasing awareness surrounding foot health, including the benefits of personalized support, plays a pivotal role in this expansion. As more individuals recognize the advantages provided by custom...

Continue Reading
Columbus McKinnon Announce Regular Dividend of $0.07

Updated Category News Views 117

Columbus McKinnon Corporation Declares Quarterly Dividend Columbus McKinnon Corporation (NASDAQ: CMCO), an established leader in intelligent motion solutions for material handling, has made a significant announcement regarding its dividend. The Board of Directors has affirmed their commitment to shareholders by declaring a regular quarterly dividend of $0.07 per common...

Continue Reading
System Integration Market Set for 13.5% Growth by 2033

Updated Category News Views 74

Understanding the Growth of the System Integration Market The global system integration market plays a vital role in the technology sector by enabling the smooth integration of various subsystems, software applications, and IT infrastructures into a unified operational framework. This market is essential for businesses looking to boost productivity, streamline processes,...

Continue Reading
Zoom Earnings Report: Analysts Revise Forecasts and Outlook

Updated Category News Views 157

Anticipation Builds for Zoom's Earnings Announcement Zoom is on the brink of dropping its fourth-quarter earnings results; brace yourself for some market action come Wednesday, February 25. This isn't just any quarterly call; it could show whether Zoom still has the magic touch or if it's leaning hard on its video-chat crutch amid growing competition and changing...

Continue Reading